August 30 commemorated a new era in cancer treatment with the U.S. Food and Drug Administration (FDA) approval of a new, cutting-edge gene therapy that reprograms a patient’s immune system to find and kill cancer cells. This highly personalized therapy known as Kymriah (previously CTL019 or tisagenlecleucel-T) signifies the promise of CAR (chimeric antigen receptor) T-cell immunotherapy, an approach that The Leukemia & Lymphoma Society (LLS) recognized early on held great promise f...
Dear Parents, LLS is collaborating with researchers at the Kennedy Krieger Institute and Johns Hopkins who are interested in learning more about the experiences and challenges of childhood cancer survivors and their caregivers related to the transition back to school after a diagnosis of cancer. According to our records, you have a school-aged or older child who has been treated for cancer and has returned to a formal school setting. We would appreciate your help by your participation in t...
In this Ask the Expert segment, a Patient Power community member wants to know if and why a bone marrow biopsy is necessary if her ET diagnosis has been confirmed by blood work. Dr. Srdan Verstovsek responds.
What are high-risk CLL chromosomal abnormalities, and how could they impact treatment? Listen as Drs. Susan Leclair and William Wierda explain.
As part of our coverage from the 2017 American Society of Clinical Oncology annual meeting, Dr. Srdan Verstovsek from The University of Texas MD Anderson Cancer Center provides a hopeful update for patients living with MPNs.
Some chemotherapy drugs have been known to affect the peripheral nerves in the nervous system, which can lead to pain, numbness or burning in your limbs, hands or feet - a condition called Chemo Induced Peripheral Neuropathy. If you’re feeling symptoms of neuropathy, talk to your doctor about what you’re experiencing. It’s a frustrating side effect, but if you’re able to be flexible in your treatment schedule, you may be able to reduce your risk by altering the timing of your treat...
August 3, 2017 (Rye Brook, NY) - The Leukemia & Lymphoma Society (LLS) applauds the U.S. Food and Drug Administration (FDA) approval today of CPX-351 (VyxeosTM), an innovative combination of two chemotherapy drugs being used to treat two high-risk subgroups of acute myeloid leukemia (AML) patients. After more than four decades of little progress in treating AML, this approval marks the third drug approval for AML patients in just the past three months. LLS contributed sustained and sign...
Patient advocate Jeff Folloder interviews Dr. John Burke, a CLL expert from Rocky Mountain Cancer Centers to learn Dr. Burke’s perspective on developing research.
Dr. Hearn Jay Cho of Mount Sinai Hospital discusses news out of ASCO 2017 and what it means for myeloma patients.
Host Andrew Schorr catches up with expert Dr. Stephen Ansell, leader of the Lymphoma Group at Mayo Clinic in Rochester, Minnesota, at the 2017 ASCO meeting in Chicago to discuss updates on Hodgkin lymphoma.
